Peer-reviewed article
Efficacy and Safety of Direct Oral Anti‐Coagulants in Painful Venous Malformations in Children
O. Boccara, Julie Bonigen, V. Soupre, Eve Puzenat, Annouk Bisdorff et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a clinical case series about the use of direct oral anticoagulant medications to treat painful venous malformations in seven children. The study found that these medications helped control pain and improved blood clotting problems without side effects. However, this is a medical treatment study focused on a specific rare condition, not on child well-being in the broader sense addressed by child development, protection, or participation research.
Key points
Limitations
This document evaluates a medical intervention for a rare vascular condition and does not address broader child well-being outcomes related to development, protection, survival, or participation.
Abstract
Direct oral anticoagulants (DOAC), including dabigatran, apixaban, and rivaroxaban, are increasingly used in adults for painful venous malformations (VMs) instead of subcutaneous drugs such as low molecular weight heparins or fondaparinux. However, these medications are poorly studied in children. In seven children with painful VMs and chronic intravascular consumptive coagulopathy, DOACs allowed for successful pain control and improvement in coagulopathy, with no adverse effects. DOACs appear to be an effective alternative in childhood VM associated with intravascular coagulopathy.